Related Experiment Video
Updated: Jul 4, 2025
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
5.8K
Emerging Technologies and Therapeutics for Type 1 Diabetes
Halis Kaan Akturk1, Alexis M McKee2
1Barbara Davis Center for Diabetes, University of Colorado, 1775 Aurora Court, Room 1319, Aurora, CO 80045, USA.
Endocrinology and Metabolism Clinics of North America
|January 25, 2024
Summary
Advancements in diabetes technology and therapeutics offer improved blood glucose control and quality of life for type 1 diabetes patients. Stem cell research is progressing towards potential cures by focusing on beta cell survival and new therapies.
Area of Science:
- Diabetes technology and therapeutics
- Stem cell research and regenerative medicine
Background:
- Recent years have seen significant progress in managing type 1 diabetes through technological and therapeutic innovations.
- These advancements enhance blood glucose management, reduce hypoglycemia, and improve overall quality of life for individuals with type 1 diabetes.
Purpose of the Study:
- To review the latest advancements in diabetes technologies and therapeutics.
- To highlight the progress in stem cell research for type 1 diabetes cure, focusing on beta cell regeneration and survival.
Main Methods:
- Review of recent literature on diabetes technology and therapeutics.
- Analysis of ongoing stem cell research, including gene editing and beta cell production.
Main Results:
- Newer diabetes technologies and therapeutics have demonstrably improved patient outcomes and confidence.
- Stem cell research is actively exploring gene editing and beta cell generation, with a key focus on enhancing cell survival.
Conclusions:
- Current diabetes management is significantly enhanced by new technologies and therapeutics, improving patient quality of life.
- Stem cell-based strategies show promise for a potential cure for type 1 diabetes, with ongoing research addressing critical challenges like cell survival and adjunctive therapies.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
01:24Glucagon-like Receptor Agonists
323
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323
01:16Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204